76 related articles for article (PubMed ID: 14986692)
21. Trial results of a new combination therapy for myeloid leukaemia.
Leach S; Richardson C; Vowles JK; Charlton L
Nurs Times; 2002 Jul 16-22; 98(29):32-4. PubMed ID: 12168413
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
[TBL] [Abstract][Full Text] [Related]
23. First-Line management of CML: a state of the art review.
Hochhaus A
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
[TBL] [Abstract][Full Text] [Related]
24. [Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha].
Molnár L; Nagy A; Dávid M; Szomor A; Méhes G; Kovács G; Losonczy H
Orv Hetil; 2004 Apr; 145(17):901-7. PubMed ID: 15170967
[TBL] [Abstract][Full Text] [Related]
25. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
26. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract][Full Text] [Related]
27. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
28. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
30. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
31. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
[TBL] [Abstract][Full Text] [Related]
32. [Chronic myeloid leukemia and imatinib mesylate therapy].
Chrobák L
Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
[No Abstract] [Full Text] [Related]
33. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
34. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
[TBL] [Abstract][Full Text] [Related]
35. Imatinib mesylate for the treatment of chronic myeloid leukemia.
Soverini S; Martinelli G; Iacobucci I; Baccarani M
Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
[TBL] [Abstract][Full Text] [Related]
36. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Giralt SA; Arora M; Goldman JM; Lee SJ; Maziarz RT; McCarthy PL; Sobocinski KA; Horowitz MM;
Br J Haematol; 2007 Jun; 137(5):461-7. PubMed ID: 17459051
[TBL] [Abstract][Full Text] [Related]
37. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
38. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
39. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cortes JE; Talpaz M; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Rios MB; Shan J; Kantarjian HM
Cancer; 2006 Mar; 106(6):1306-15. PubMed ID: 16463391
[TBL] [Abstract][Full Text] [Related]
40. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]